VahatiCor Enrolls First U.S. Patient in SERRA-I Clinical Study of A-FLUX Reducer System® for CMD

A-FLUX Reducer System® enters U.S. clinical evaluation in the SERRA-I early feasibility study SANTA CLARA, Calif., June 17, 2026 /PRNewswire/ -- VahatiCor, Inc., a medtech company developing interventional therapies for coronary microvascular dysfunction (CMD), today announced the...